世界のヘルペス治療市場 2019年

【英語タイトル】Global Herpes Treatment Market Professional Survey Report 2019

QYResearchが出版した調査資料(QYR20FB01988)・商品コード:QYR20FB01988
・発行会社(調査会社):QYResearch
・発行日:2019年10月(※2024年版があります。お問い合わせください)
・ページ数:104
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,500 ⇒換算¥518,000見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,250 ⇒換算¥777,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥1,036,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
※本調査レポートは、ヘルペス治療の世界市場概要、製造コスト分析、開発・製造工場分析、主要メーカー分析、地域別分析情報、市場規模予測データ、マーケティングチャネル、流通業者リスト、顧客リストなどが含まれています。種類別には、アシクロビル、バラシクロビル、ファムシクロビルに、用途別には、病院薬局、小売薬局、オンライン薬局、ドラッグストアにセグメント区分し、ヘルペス治療の世界市場を分析しました。


・エグゼクティブ・サマリー
・ヘルペス治療の世界市場概要
・ヘルペス治療の製造コスト構成分析
・ヘルペス治療の開発・製造工場分析
・主要メーカーの主な指標(生産能力、売上、価格分析)
・ヘルペス治療の地域別分析(生産、売上、主要メーカー、輸出・輸入)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・ヘルペス治療のセグメント分析(種類別)
(アシクロビル、バラシクロビル、ファムシクロビル)
・ヘルペス治療のセグメント分析(用途別)
(病院薬局、小売薬局、オンライン薬局、ドラッグストア)
・ヘルペス治療の主要メーカー別分析(生産拠点、製品概要、生産・売上実績)
(Gilead、GlaxoSmithKline、Merck、Novartis、Abbott、Mylan、Teva Pharmaceutical Industries、Vical)
・ヘルペス治療の市場規模予測(2019年~2025年)
(北米、ヨーロッパ、中国、日本国内、東南アジア、インド)
・マーケティングチャネル・流通業者・顧客
・市場ダイナミクス(市場動向、機会、成長要因、課題、影響因子)
...
【レポートの概要】

Genital herpes is a common sexually transmitted disease. With the increase in population of various regions, there is also an increase in the rate of health issues around the world. As the rate of diseases grow, the treatment markets are also expected to grow substantially. With respect to sexually transmitted disease like genital herpes, its treatment market includes different drug types like Acyclovir, Valacyclovir and Famciclovir. The indication of genital herpes include HSV-1 and HSV-2. The rising prevalence of shingles or herpes zoster in the older population is one of the key drivers responsible for the market’s growth. According to the center for disease control and prevention (CDC), almost one in every three individuals in the US are likely to develop shingles during their lifetime. People aged 50 years and above can develop this disease due to weakened immune system. Complications associated with this disease such as post-herpetic neuralgia (PHN) can cause severe pain in the areas where the rashes occurred due to shingles. People administered with immunosuppressants in the past can also develop the disease. CDC recommends that one dose of the zoster vaccine must be prescribed to adults who are 60 years and above to reduce the probability of the disease and PHN. This will drive the demand for drugs for virus types such as herpes simplex and herpes zoster, subsequently fueling market growth.
One of the key trends that will stimulate growth in the global herpes treatment market in the coming years is the emergence of novel therapies. GEN-003 vaccine, developed by Genocea is under clinical trials and is effective in controlling both the shedding and outbreak of herpes simplex virus or HSV-2 infection. Shingrix vaccine developed for the treatment of herpes zoster or shingles is also expected to change the market landscape once launched in the forthcoming years.

The global Herpes Treatment market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Herpes Treatment volume and value at global level, regional level and company level. From a global perspective, this report represents overall Herpes Treatment market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Herpes Treatment in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Herpes Treatment manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Gilead
GlaxoSmithKline
Merck
Novartis
Abbott
Mylan
Teva Pharmaceutical Industries
Vical

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Acyclovir
Valacyclovir
Famciclovir

Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Drug Stores

【レポートの目次】

Table of Contents

Executive Summary
1 Industry Overview of Herpes Treatment
1.1 Definition of Herpes Treatment
1.2 Herpes Treatment Segment by Type
1.2.1 Global Herpes Treatment Production Growth Rate Comparison by Types (2014-2025)
1.2.2 Acyclovir
1.2.3 Valacyclovir
1.2.4 Famciclovir
1.3 Herpes Treatment Segment by Applications
1.3.1 Global Herpes Treatment Consumption Comparison by Applications (2014-2025)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Drug Stores
1.4 Global Herpes Treatment Overall Market
1.4.1 Global Herpes Treatment Revenue (2014-2025)
1.4.2 Global Herpes Treatment Production (2014-2025)
1.4.3 North America Herpes Treatment Status and Prospect (2014-2025)
1.4.4 Europe Herpes Treatment Status and Prospect (2014-2025)
1.4.5 China Herpes Treatment Status and Prospect (2014-2025)
1.4.6 Japan Herpes Treatment Status and Prospect (2014-2025)
1.4.7 Southeast Asia Herpes Treatment Status and Prospect (2014-2025)
1.4.8 India Herpes Treatment Status and Prospect (2014-2025)

2 Manufacturing Cost Structure Analysis
2.1 Raw Material and Suppliers
2.2 Manufacturing Cost Structure Analysis of Herpes Treatment
2.3 Manufacturing Process Analysis of Herpes Treatment
2.4 Industry Chain Structure of Herpes Treatment

3 Development and Manufacturing Plants Analysis of Herpes Treatment
3.1 Capacity and Commercial Production Date
3.2 Global Herpes Treatment Manufacturing Plants Distribution
3.3 Major Manufacturers Technology Source and Market Position of Herpes Treatment
3.4 Recent Development and Expansion Plans

4 Key Figures of Major Manufacturers
4.1 Herpes Treatment Production and Capacity Analysis
4.2 Herpes Treatment Revenue Analysis
4.3 Herpes Treatment Price Analysis
4.4 Market Concentration Degree

5 Herpes Treatment Regional Market Analysis
5.1 Herpes Treatment Production by Regions
5.1.1 Global Herpes Treatment Production by Regions
5.1.2 Global Herpes Treatment Revenue by Regions
5.2 Herpes Treatment Consumption by Regions
5.3 North America Herpes Treatment Market Analysis
5.3.1 North America Herpes Treatment Production
5.3.2 North America Herpes Treatment Revenue
5.3.3 Key Manufacturers in North America
5.3.4 North America Herpes Treatment Import and Export
5.4 Europe Herpes Treatment Market Analysis
5.4.1 Europe Herpes Treatment Production
5.4.2 Europe Herpes Treatment Revenue
5.4.3 Key Manufacturers in Europe
5.4.4 Europe Herpes Treatment Import and Export
5.5 China Herpes Treatment Market Analysis
5.5.1 China Herpes Treatment Production
5.5.2 China Herpes Treatment Revenue
5.5.3 Key Manufacturers in China
5.5.4 China Herpes Treatment Import and Export
5.6 Japan Herpes Treatment Market Analysis
5.6.1 Japan Herpes Treatment Production
5.6.2 Japan Herpes Treatment Revenue
5.6.3 Key Manufacturers in Japan
5.6.4 Japan Herpes Treatment Import and Export
5.7 Southeast Asia Herpes Treatment Market Analysis
5.7.1 Southeast Asia Herpes Treatment Production
5.7.2 Southeast Asia Herpes Treatment Revenue
5.7.3 Key Manufacturers in Southeast Asia
5.7.4 Southeast Asia Herpes Treatment Import and Export
5.8 India Herpes Treatment Market Analysis
5.8.1 India Herpes Treatment Production
5.8.2 India Herpes Treatment Revenue
5.8.3 Key Manufacturers in India
5.8.4 India Herpes Treatment Import and Export

6 Herpes Treatment Segment Market Analysis (by Type)
6.1 Global Herpes Treatment Production by Type
6.2 Global Herpes Treatment Revenue by Type
6.3 Herpes Treatment Price by Type

7 Herpes Treatment Segment Market Analysis (by Application)
7.1 Global Herpes Treatment Consumption by Application
7.2 Global Herpes Treatment Consumption Market Share by Application (2014-2019)

8 Herpes Treatment Major Manufacturers Analysis
8.1 Gilead
8.1.1 Gilead Herpes Treatment Production Sites and Area Served
8.1.2 Gilead Product Introduction, Application and Specification
8.1.3 Gilead Herpes Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.1.4 Main Business and Markets Served
8.2 GlaxoSmithKline
8.2.1 GlaxoSmithKline Herpes Treatment Production Sites and Area Served
8.2.2 GlaxoSmithKline Product Introduction, Application and Specification
8.2.3 GlaxoSmithKline Herpes Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.2.4 Main Business and Markets Served
8.3 Merck
8.3.1 Merck Herpes Treatment Production Sites and Area Served
8.3.2 Merck Product Introduction, Application and Specification
8.3.3 Merck Herpes Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.3.4 Main Business and Markets Served
8.4 Novartis
8.4.1 Novartis Herpes Treatment Production Sites and Area Served
8.4.2 Novartis Product Introduction, Application and Specification
8.4.3 Novartis Herpes Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.4.4 Main Business and Markets Served
8.5 Abbott
8.5.1 Abbott Herpes Treatment Production Sites and Area Served
8.5.2 Abbott Product Introduction, Application and Specification
8.5.3 Abbott Herpes Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.5.4 Main Business and Markets Served
8.6 Mylan
8.6.1 Mylan Herpes Treatment Production Sites and Area Served
8.6.2 Mylan Product Introduction, Application and Specification
8.6.3 Mylan Herpes Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.6.4 Main Business and Markets Served
8.7 Teva Pharmaceutical Industries
8.7.1 Teva Pharmaceutical Industries Herpes Treatment Production Sites and Area Served
8.7.2 Teva Pharmaceutical Industries Product Introduction, Application and Specification
8.7.3 Teva Pharmaceutical Industries Herpes Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.7.4 Main Business and Markets Served
8.8 Vical
8.8.1 Vical Herpes Treatment Production Sites and Area Served
8.8.2 Vical Product Introduction, Application and Specification
8.8.3 Vical Herpes Treatment Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
8.8.4 Main Business and Markets Served

9 Development Trend of Analysis of Herpes Treatment Market
9.1 Global Herpes Treatment Market Trend Analysis
9.1.1 Global Herpes Treatment Market Size (Volume and Value) Forecast 2019-2025
9.2 Herpes Treatment Regional Market Trend
9.2.1 North America Herpes Treatment Forecast 2019-2025
9.2.2 Europe Herpes Treatment Forecast 2019-2025
9.2.3 China Herpes Treatment Forecast 2019-2025
9.2.4 Japan Herpes Treatment Forecast 2019-2025
9.2.5 Southeast Asia Herpes Treatment Forecast 2019-2025
9.2.6 India Herpes Treatment Forecast 2019-2025
9.3 Herpes Treatment Market Trend (Product Type)
9.4 Herpes Treatment Market Trend (Application)

10.1 Marketing Channel
10.1.1 Direct Marketing
10.1.2 Indirect Marketing
10.3 Herpes Treatment Customers

11 Market Dynamics
11.1 Market Trends
11.2 Opportunities
11.3 Market Drivers
11.4 Challenges
11.5 Influence Factors

12 Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Author List
13.4 Disclaimer



【掲載企業】

Gilead、GlaxoSmithKline、Merck、Novartis、Abbott、Mylan、Teva Pharmaceutical Industries、Vical

★調査レポート[世界のヘルペス治療市場 2019年] (コード:QYR20FB01988)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界のヘルペス治療市場 2019年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆